Regentis Biomaterials Ltd. (RGNT) stock
RGNTNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Feb 24, 2026Score 1/30
$1.14−0.08 (-6.56%)
Close on Nov 18, 2026Market cap $5.90MP/E –Yield –
Regentis Biomaterials operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was -$6.97M, down 847.6% from the year before.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$6.97M | -847.6% |
| FY2024 | Dec 31, 2024 | $932.00K | – |
| FY2023 | Dec 31, 2023 | -$1.93M | – |
See a number that looks wrong?